Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 8/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.39 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.39 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1897176 | 0.83 | GRIK1 (0.55) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL12191191 | 0.83 | GRIK1 (0.55) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL9651132 | 0.82 | FFAR3 (0.39) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL27734834 | 0.79 | GAPDH (0.37) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL14891395 | 0.79 | TSHR (0.48) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL31028121 | 0.79 | GRIK1 (0.38) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL3240320 | 0.76 | ALDH1A1 (0.39) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL2703569 | 0.76 | GRIK1 (0.32) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL6661767 | 0.76 | GPR84 (0.47) | TSHR | |
| SCHEMBL2203074 | 0.74 | GRIK1 (0.35) | GRIK1GRIK2GRIA2GRIA4GRIK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263873-A1 | Enantioselective Synthesis of y-amino-alpha beta-unsaturated carboxylic acid derivatives | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263873-A1 | Enantioselective Synthesis of y-amino-alpha beta-unsaturated carboxylic acid derivatives | BCAT1, BCAT2, AADAT | GRIK1 1142/4885GRIK2 936/4885GRIA2 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.